Division of Internal Medicine.
Division of Gastroenterology and Hepatology, Mayo Clinic Florida, Jacksonville, Florida, USA.
Curr Opin Gastroenterol. 2024 Nov 1;40(6):470-476. doi: 10.1097/MOG.0000000000001045. Epub 2024 Jun 12.
Functional dyspepsia is a common gastrointestinal disease that is under-recognized and under-diagnosed. It is a complex disorder of gut-brain interaction with no FDA-approved treatment options. The purpose of this review is to highlight updates in the proposed pathophysiology and present new data regarding potential therapies for functional dyspepsia.
Alterations in the intestinal microbiome and integrity of the intestinal membrane may play a crucial role in the pathogenesis of functional dyspepsia. The low FODMAP diet, in addition to modulating the microbiome with antibiotics and probiotics, are targets for large future studies. Novel methods of delivery of gut-brain therapies have shown promising results, especially virtual reality.
The pathophysiology and management of functional dyspepsia is complex and there is still much unknown; however, continued research is identifying new targets for treatment. New and more targeted treatment options provide clinicians a variety of tools to offer patients with functional dyspepsia.
功能性消化不良是一种常见的胃肠道疾病，未被充分认识和诊断。它是一种复杂的肠-脑相互作用紊乱，没有获得 FDA 批准的治疗方法。本文的目的是强调提出的发病机制的更新，并提供有关功能性消化不良潜在治疗方法的新数据。
肠道微生物组的改变和肠道膜的完整性可能在功能性消化不良的发病机制中起关键作用。除了用抗生素和益生菌来调节微生物组外，低 FODMAP 饮食也是未来大型研究的目标。肠道-大脑治疗方法的新传递方法显示出有希望的结果，特别是虚拟现实。
功能性消化不良的发病机制和治疗方法很复杂，仍有许多未知；然而，持续的研究正在为治疗确定新的靶点。新的、更有针对性的治疗选择为临床医生提供了多种工具，为功能性消化不良患者提供了更多的选择。
